(VIANEWS) – Shares of BIOSENIC (BEL 20: BIOS.BR) slid by a staggering 24.59% in 10 sessions from €0.17 to €0.13 at 16:12 EST on Wednesday, after four successive sessions in a row of losses. BEL 20 is dropping 2.29% to €3,643.16, after five sequential sessions in a row of losses.
About BIOSENIC
BioSenic S.A., a biotech company, focuses on developing clinical assets. Its technologies include cutting-edge allogeneic cell and gene therapy platform with differentiated bone marrow sourced mesenchymal stromal cells, which can be stored at the point of use in the hospital; and Arsenic TriOxide platform for use in immuno-oncology to treat graft-versus-host disease, systemic lupus erythematosus, and systemic sclerosis. The company's investigational medicinal product is ALLOB, which is in a Phase IIb clinical trial in patients with difficult tibial fractures. The company is based in Mont-Saint-Guibert, Belgium.
Volume
Today’s last reported volume for BIOSENIC is 95805 which is 67.54% below its average volume of 293043.
Volatility
BIOSENIC’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.13%, a negative 2.35%, and a positive 6.28%.
BIOSENIC’s highest amplitude of average volatility was 3.13% (last week), 6.73% (last month), and 6.28% (last quarter).
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, BIOSENIC’s stock is considered to be overbought (>=80).
More news about BIOSENIC (BIOS.BR).
